David C Kaslow

US Patent:

6733993, May 11, 2004

Filed:

Sep 14, 2001

Appl. No.:

09/952060

Inventors:

Emilio A. Emini - Wayne PA
Rima Youil - North Wales PA
Andrew J. Bett - Landsdale PA
Ling Chen - Blue Bell PA
David C. Kaslow - Bryn Mawr PA
John W. Shiver - Doylestown PA
Timothy J. Toner - Marlton NJ
Danilo R. Casimiro - Harleysville PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C12P 2106

US Classification:

435 691, 435 5, 435 71, 435325, 4353391, 53038835, 536 231, 4241991, 4242081

Abstract:

First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

US Patent:

6780417, Aug 24, 2004

Filed:

Mar 2, 1995

Appl. No.:

08/400421

Inventors:

David C. Kaslow - Kensington MD
Stuart Isaacs - Kensington MD
Bernard Moss - Bethesda MD

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39015

US Classification:

4241991, 4241911, 4242681, 4242721, 435 693, 4353201

Abstract:

The present invention relates to transmission blocking vaccines against malaria. Vaccines of the present invention contain a recombinant virus encoding all, or a unique portion, of the 25 kDa sexual stage surface protein of , Pfs25, or the Pfs25 protein purified from host cells infected with the above-described recombinant virus. Mice inoculated with the recombinant virus developed antibodies with transmission blocking activity. The present invention also relates to recombinant viruses used in the vaccines of the present invention, host cells infected with the recombinant viruses of the present invention and methods of preventing or treating malarial infections using the vaccines of the present invention.

US Patent:

7192934, Mar 20, 2007

Filed:

Dec 4, 1998

Appl. No.:

09/554960

Inventors:

David C. Kaslow - Rancho Santa Fe CA, US
Takafumi Tsuboi - Shigenobu-cho, JP
Motomi Torii - Tobe-cho, JP

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A01N 43/04
A61K 31/70
C07H 21/02
C07H 21/04

US Classification:

514 44, 536 231, 536 237

Abstract:

The present invention relates to novel methods and compositions for blocking transmission of which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.

US Patent:

7407658, Aug 5, 2008

Filed:

Dec 15, 2006

Appl. No.:

11/611779

Inventors:

David C. Kaslow - Wayne PA, US
Takafumi Tsuboi - Ehime, JP
Motomi Torii - Ehime, JP

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/015

US Classification:

4241851, 4242721

Abstract:

The present invention relates novel methods and compositions for blocking transmission of which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants, including deglycosylated forms, and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria.

US Patent:

7598362, Oct 6, 2009

Filed:

Oct 10, 2002

Appl. No.:

10/492178

Inventors:

Emilio A. Emini - Wayne PA, US
David C. Kaslow - Rancho Santa Fe CA, US
Andrew J. Bett - Lansdale PA, US
John W. Shiver - Chalfont PA, US
Alfredo Nicosia - Rome, IT
Armin Lahm - Rome, IT
Alessandra Luzzago - Rome, IT
Riccardo Cortese - Rome, IT
Stefano Colloca - Rome, IT

Assignee:

Merck & Co., Inc. - Rahway NJ
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A. - Rome

International Classification:

C07H 21/04
C12N 7/00

US Classification:

536 231, 536 234, 4242181

Abstract:

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.

US Patent:

8142794, Mar 27, 2012

Filed:

Mar 3, 2009

Appl. No.:

12/396747

Inventors:

Emilio A. Emini - Wayne PA, US
David C. Kaslow - Rancho Santa Fe CA, US
Andrew J. Bett - Lansdale PA, US
John W. Shiver - Chalfont PA, US
Alfredo Nicosia - Rome, IT
Armin Lahm - Rome, IT
Alessandra Luzzago - Rome, IT
Riccardo Cortese - Rome, IT
Stefano Colloca - Rome, IT

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12N 7/00
C07H 21/04

US Classification:

4242181, 4241891, 536 231, 536 234

Abstract:

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.

US Patent:

8530234, Sep 10, 2013

Filed:

Dec 8, 2009

Appl. No.:

12/633104

Inventors:

David C. Kaslow - Rancho Santa Fe CA, US
Andrew J. Bett - Lansdale PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C12N 15/63
C07H 21/04
A61K 48/00

US Classification:

4353201, 536 231, 514 44, 4352523

Abstract:

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.

US Patent:

20040101957, May 27, 2004

Filed:

Mar 14, 2003

Appl. No.:

10/380641

Inventors:

Emilio Emini - Wayne PA, US
Rima Youil - North Wales PA, US
Andrew Bett - Lansdale PA, US
Ling Chen - Blue Bell PA, US
David Kaslow - Rancho Santa Fe CA, US
John Shiver - Chalfont PA, US
Timothy Toner - Marlton NJ, US
Danilo Casimiro - Harleysville PA, US

International Classification:

C12Q001/68
C12P021/06
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

US Classification:

435/320100, 435/069100, 435/006000

Abstract:

First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.